Am J Physiol Lung Cell Mol Physiol

. 2023 Dec 19.

 doi: 10.1152/ajplung.00096.2023. Online ahead of print. https://pubmed.ncbi.nlm.nih.gov/38113296/

Direct Thrombin Inhibitors Fail to Reverse the Negative Effects of Heparin on Lung Growth and Function after Murine Left Pneumonectomy

Savas T Tsikis ¹, Thomas I Hirsch ¹, Timothy Klouda ², Scott C Fligor ¹, Amy Pan ³, Malachi M Joiner ¹, Sarah Z Wang ⁴, Mikayla Quigley ¹, Angela Devietro ¹, Paul D Mitchell ⁵, Hiroko Kishikawa ¹, Ke Yuan ⁶, Mark Puder ¹

Affiliations expand

• PMID: 38113296
• DOI: 10.1152/ajplung.00096.2023

Abstract

Neonates with congenital diaphragmatic hernia (CDH) frequently require cardiopulmonary bypass and systemic anticoagulation. We previously demonstrated that even subtherapeutic heparin impairs lung growth and function in a murine model of compensatory lung growth. The direct thrombin inhibitors (DTIs) bivalirudin and argatroban preserved growth in this model. While DTIs are increasingly used for systemic anticoagulation clinically, CDH patients may still receive heparin. In this experiment, lung endothelial cell proliferation was assessed following treatment with heparin-alone or mixed with increasing concentrations of bivalirudin or argatroban. The effects of subtherapeutic heparin with or without DTIs in the CLG model was also investigated. C57BL/6J mice underwent left pneumonectomy and subcutaneous implantation of osmotic pumps. Pumps were pre-loaded with normal saline, bivalirudin, or argatroban; treated animals received daily intraperitoneal low-dose heparin. In vitro, heparin-alone decreased endothelial cell proliferation and increased apoptosis. The effect of heparin on proliferation, but not apoptosis, was reversed by the addition of bivalirudin and argatroban. In vivo, low-dose heparin decreased lung volume compared to saline-treated controls. All three groups that received heparin demonstrated decreased lung function on pulmonary function testing and impaired exercise performance on treadmill tolerance testing. These findings correlated with decreases in alveolarization, vascularization, angiogenic signaling and gene expression in the heparin-exposed groups. Together, these data suggest that bivalirudin and argatroban fail to reverse the inhibitory effects of subtherapeutic heparin on lung growth and function. Clinical studies on the impact of low-dose heparin with DTIs on CDH outcomes are warranted.

Keywords: anticoagulation; compensatory lung growth; congenital diaphragmatic hernia; heparin; pulmonary hypoplasia.